Bioextrax (BIOEX) Q4 2024 earnings summary

Executive summary

• Focused on commercializing bioplastics (PHA), protein, and microfibers from feathers using proprietary biotech processes; strategic partnerships and licensing model drive growth.

• Major organizational restructuring in 2024 reduced costs and improved efficiency; no further major investments or recruitments planned for 2025.

• Upscaling facility operational, enabling larger test volumes and accelerating customer projects toward commercial licensing.

Financial highlights

• Q4 2024 net sales: 122 tkr (810 tkr Q4 2023); full-year 2024: 515 tkr (2,056 tkr 2023).

• Q4 2024 operating result: -4,088 tkr (-6,322 tkr Q4 2023); full-year 2024: -17,539 tkr (-21,599 tkr 2023).

• Q4 2024 EPS: -0.11 SEK (-0.21); full-year 2024 EPS: -0.52 SEK (-0.81).

• Q4 2024 cash flow: 8,243 tkr (-5,126 tkr Q4 2023); full-year 2024: 3,868 tkr (-14,133 tkr 2023).

• Cash and cash equivalents at year-end: 17,267 tkr (13,399 tkr 2023); equity at year-end: 26,059 tkr (20,536 tkr 2023).

Outlook and guidance

• Sufficient liquidity after 14.5 MSEK rights issue to fund operations for the next 12 months; focus on increasing license revenues.

• No dividend proposed for 2024.

• No significant events after the reporting period.